Received Dec. 23, 1998; revision received Feb. 8, 2000; accepted Mar. 13, 2000. From the Medical College of Virginia, Virginia Commonwealth University; Stanford University School of Medicine, Stanford, Calif.; the University of Pittsburgh and Western Psychiatric Institute, Pittsburgh; the Yale University School of Medicine, New Haven, Conn.; the Department of Psychology, Virginia Commonwealth University; Brown University, Providence, R.I.; the University of Arizona, Tucson; Quintiles, Inc., Research Triangle Park, N.C.; Pfizer, Inc., New York; and the College of Physicians and Surgeons, Columbia University School of Medicine, New York. Address reprint requests to Dr. Kornstein, Department of Psychiatry, Medical College of Virginia, Virginia Commonwealth University, P.O. Box 980710, Richmond, VA 23298-0710; firstname.lastname@example.org (e-mail). This study was completed under contracts from Pfizer Pharmaceuticals to the following investigators: Martin B. Keller, M.D. (Program Director), Gabor I. Keitner, M.D., and Ivan W. Miller, Ph.D., Brown University; James H. Kocsis, M.D., and John C. Markowitz, M.D., Cornell University; Daniel N. Klein, Ph.D., Fritz Henn, M.D., and David Schlager, M.D., State University of New York at Stony Brook; James P. McCullough, Ph.D., and Susan G. Kornstein, M.D., Virginia Commonwealth University; Robert M.A. Hirschfeld, M.D., and James Russell, M.D., University of Texas, Galveston; Michael E. Thase, M.D., and Robert Howland, M.D., University of Pittsburgh; John S. Carman, M.D., psychiatry and research, Atlanta; A. John Rush, M.D., and George Trapp, M.D., University of Texas Southwestern; Alan F. Schatzberg, M.D., and Lorrin Koran, M.D., Stanford University; Alan J. Gelenberg, M.D., and Pedro Delgado, M.D., University of Arizona; John Feighner, M.D., Feighner Research Institute; and Jan A. Fawcett, M.D., and John Zajecka, M.D., Rush Institute for Mental Well-Being.